Literature DB >> 1703067

Simultaneous measurement of DNA content and cell-surface immunofluorescence of human bone marrow cells using a single laser flow cytometer.

P P Brons1, A H Pennings, C Haanen, H M Wessels, J B Boezeman.   

Abstract

This paper describes the measurement of S phase DNA content in human bone marrow subpopulations using a single laser method for bivariate analysis of DNA content and cell-surface immunofluorescence (s-IF). Low density (less than 1.077 g/ml) bone marrow cells were labeled with a panel of unconjugated monoclonal antibodies (MoAb) for the lymphoid (CD2 + CD19), T-lymphoid (CD2), B-lymphoid (CD19), erythroid (anti-glycophorin-A), myelomonocytic (CD13, CD33; single and as cocktail) and monocytic (CD14) lineages. A fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse label was used as second step. Unfixed, MoAb-labeled cells were incubated for 24 h with a hypotonic propidium iodide solution for DNA staining. Cells were analysed on a single-laser flow cytometer, operating at 488 nm. The effect of the combined staining protocol upon both s-IF and DNA stainability was evaluated. Only a slight decrease (mean: 29.0%) in s-IF intensity was observed after DNA staining. The percentages of immunofluorescent cells in the bone marrow samples of 10 normal individuals before and after DNA staining were essentially unchanged for all the MoAbs used. The DNA histograms of the immunophenotypically defined subpopulations were of excellent quality with a mean coefficient or variation of 1.8%. This procedure allows the assessment of very low levels of S-phase DNA content, as measured in normal low density blood cells of 8 healthy volunteers (mean 0.07%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703067     DOI: 10.1002/cyto.990110710

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  7 in total

1.  Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time.

Authors:  P P Brons; N Van der Lely; C Haanen; A H Pennings; J B Boezeman; J M Wessels; R A Raijmakers; T J de Witte
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

2.  Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas.

Authors:  M A Weterman; J J van Groningen; L Tertoolen; A G van Kessel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  The mitotic arrest deficient protein MAD2B interacts with the clathrin light chain A during mitosis.

Authors:  Klaas Medendorp; Lilian Vreede; Jan J M van Groningen; Lisette Hetterschijt; Linda Brugmans; Patrick A M Jansen; Wilhelmina H van den Hurk; Diederik R H de Bruijn; Ad Geurts van Kessel
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

4.  hZAC encodes a zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer.

Authors:  A Varrault; E Ciani; F Apiou; B Bilanges; A Hoffmann; C Pantaloni; J Bockaert; D Spengler; L Journot
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

5.  Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics.

Authors:  P P Brons; C Haanen; J B Boezeman; P Muus; R S Holdrinet; A H Pennings; H M Wessels; T de Witte
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

6.  The mitotic arrest deficient protein MAD2B interacts with the small GTPase RAN throughout the cell cycle.

Authors:  Klaas Medendorp; Jan J M van Groningen; Lilian Vreede; Lisette Hetterschijt; Wilhelmina H van den Hurk; Diederik R H de Bruijn; Linda Brugmans; Ad Geurts van Kessel
Journal:  PLoS One       Date:  2009-09-15       Impact factor: 3.240

7.  Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor beta.

Authors:  Y Takahama; J J Letterio; H Suzuki; A G Farr; A Singer
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.